These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24507938)

  • 1. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
    Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
    Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of second malignancies after
    Fernandez Ots A; Browne L; Chin YS; Malouf D; Wong K; Bucci J
    Brachytherapy; 2016; 15(6):752-759. PubMed ID: 27475483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
    Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
    Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
    J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
    Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
    Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
    BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
    Vigneault E; Martell K; Taussky D; Husain S; Delouya G; Mbodji K; Piotte J; Magnan S; Després P; Lavallée MC; Aubin S; Beaulieu L; Foster W; Martin AG
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1190-1194. PubMed ID: 29428250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer incidence after localized therapy for prostate cancer.
    Moon K; Stukenborg GJ; Keim J; Theodorescu D
    Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
    Vuolukka K; Auvinen P; Palmgren JE; Aaltomaa S; Kataja V
    BMC Cancer; 2020 May; 20(1):453. PubMed ID: 32434560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.
    International Commission on Radiological Protection
    Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
    Abdel-Wahab M; Reis IM; Hamilton K
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model.
    Takam R; Bezak E; Yeoh EE
    Phys Med Biol; 2009 Feb; 54(3):611-25. PubMed ID: 19124952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
    Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of colon cancer after external radiation therapy for prostate cancer.
    Rapiti E; Fioretta G; Verkooijen HM; Zanetti R; Schmidlin F; Shubert H; Merglen A; Miralbell R; Bouchardy C
    Int J Cancer; 2008 Sep; 123(5):1141-5. PubMed ID: 18546265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.
    Singh AK; Mashtare TL; McCloskey SA; Seixas-Mikelus SA; Kim HL; May KS
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1086-94. PubMed ID: 20350797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
    Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
    BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
    Gottschalk A
    Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.